Stock data
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX) reported net income of -US$227.32M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$244.83M | -US$227.32M | — |
| 2024 | — | — | -US$143.09M | -US$118.94M | — |
| 2023 | — | — | -US$54.12M | -US$36.01M | — |
| 2022 | — | — | -US$65.06M | -US$49.97M | — |
| 2021 | — | — | -US$53.58M | -US$53.64M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$61.80M | — |
| 2026-03-31 | — | -US$69.71M | — |
| 2025-12-31 | — | -US$62.42M | — |
| 2025-09-30 | — | -US$69.73M | — |
| 2025-06-30 | — | -US$55.22M | — |
| 2025-03-31 | — | -US$39.94M | — |
| 2024-12-31 | — | -US$45.61M | — |
| 2024-09-30 | — | -US$35.39M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.